(Q50629816)

16 March 2018

title

Understanding patient compliance and persistence with osteoporosis therapy. (English)

1 reference

16 March 2018

0 references

1

Deborah T Gold

1 reference

16 March 2018

publication date

1 April 2011

1 reference

16 March 2018

published in

Drugs & Aging

1 reference

16 March 2018

volume

28

1 reference

16 March 2018

issue

4

1 reference

16 March 2018

page(s)

249-255

1 reference

16 March 2018

https://scigraph.springernature.com/pub.10.2165/11586880-000000000-00000

exact match

0 references

cites work

Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Efficacy of risedronate on clinical vertebral fractures within six months.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Early discontinuation of treatment for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Compliance with drug therapies for the treatment and prevention of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Tolerability and compliance with risedronate in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Medication compliance and persistence: terminology and definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

A checklist for medication compliance and persistence studies using retrospective databases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Measuring and improving adherence to osteoporosis pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Impact of osteoporosis treatment adherence on fracture rates in North America and Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Studying prescription drug use and outcomes with medicaid claims data: strengths, limitations, and strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Compliance and persistence with osteoporosis medications: a critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Methodological considerations in using claims databases to evaluate persistence with bisphosphonates for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

The use of claims databases for outcomes research: rationale, challenges, and strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

A systematic review of persistence and compliance with bisphosphonates for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Improving compliance and persistence with bisphosphonate therapy for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Patient adherence to osteoporosis medications: problems, consequences and management strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Understanding medication compliance and persistence from an economics perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Adherence to medicines in the older-aged with chronic conditions: does intervention by an allied health professional help?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

A blinded randomized controlled trial of motivational interviewing to improve adherence with osteoporosis medications: design of the OPTIMA trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586880-000000000-00000

Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis

21 January 2018

1 reference

12 December 2020

An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study

1 reference

12 December 2020

Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate

1 reference

12 December 2020

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

1 reference

12 December 2020

Effect of Monitoring Bone Turnover Markers on Persistence with Risedronate Treatment of Postmenopausal Osteoporosis

1 reference

12 December 2020

Inclusion of older women in randomized clinical trials: factors associated with taking study medication in the fracture intervention trial

1 reference

12 December 2020

Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women

1 reference

12 December 2020

Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis

1 reference

12 December 2020

10.2165/11586880-000000000-00000

Identifiers

DOI

1 reference

16 March 2018

Dimensions Publication ID

0 references

1 reference

16 March 2018